<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37055494</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Prevalence of long COVID complaints in persons with and without COVID-19.</ArticleTitle><Pagination><StartPage>6074</StartPage><MedlinePgn>6074</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6074</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-32636-y</ELocationID><Abstract><AbstractText>We studied the prevalence and patterns of typical long COVID complaints in&#x2009;~&#x2009;2.3&#xa0;million individuals aged 18-70&#xa0;years with and without confirmed COVID-19 in a Nation-wide population-based prospective cohort study in Norway. Our main outcome measures were the period prevalence of single-occurring or different combinations of complaints based on medical records: (1) Pulmonary (dyspnea and/or cough), (2) Neurological (concentration problems, memory loss), and/or (3) General complaints (fatigue). In persons testing positive (n&#x2009;=&#x2009;75&#xa0;979), 64 (95% confidence interval: 54 to 73) and 122 (111 to 113) more persons per 10&#xa0;000 persons had pulmonary complaints 5-6&#xa0;months after the test compared to 10&#xa0;000 persons testing negative (n&#x2009;=&#x2009;1&#xa0;167&#xa0;582) or untested (n&#x2009;=&#x2009;1&#xa0;084&#xa0;578), respectively. The corresponding difference in prevalence of general complaints (fatigue) was 181 (168 to 195) and 224 (211 to 238) per 10&#xa0;000, and of neurological complaints 5 (2 to 8) and 9 (6-13) per 10&#xa0;000. Overlap between complaints was rare. Long COVID complaints were only slightly more prevalent in persons with than without confirmed COVID-19. Still, long COVID may pose a substantial burden to healthcare systems in the future given the lasting high incidence of symptomatic COVID-19 in both vaccinated and unvaccinated individuals.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Magnusson</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Norwegian Institute of Public Health, Cluster for Health Services Research, Sandakerveien 24C, 0473, Oslo, Norway. karin.magnusson@fhi.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Clinical Sciences Lund, Orthopaedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden. karin.magnusson@fhi.no.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway. karin.magnusson@fhi.no.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turkiewicz</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Clinical Sciences Lund, Orthopaedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flottorp</LastName><ForeName>Signe Agnes</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Norwegian Institute of Public Health, Cluster for Health Services Research, Sandakerveien 24C, 0473, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Englund</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Clinical Sciences Lund, Orthopaedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>We declare no conflicts of interest, except for Dr. Englund reporting grants from The Swedish Research Council, grants from &#xd6;sterlund Foundation, grants from Governmental Funding of Clinical Research within National Health Service (ALF), grants from Greta and Johan Kock Foundations, grants from The Swedish Rheumatism Association, during the conduct of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37055494</ArticleId><ArticleId IdType="pmc">PMC10100609</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-32636-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-32636-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flatby AF, Himmels JPW, Brurberg KG, Gravningen KM. COVID-19: Post COVID19 Condition [Senf&#xf8;lger Etter Covid-19 Hurtigoversikt 2022] Norwegian institute of public health; 2022.</Citation></Reference><Reference><Citation>Lund LC, et al. Post-acute effects of SARSCoV-2 infection in individuals not requiring hospital admission: A Danish population-based cohort study. Lancet Infect. Dis. 2021;21:1373&#x2013;1382. doi: 10.1016/S1473-3099(21)00211-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00211-5</ArticleId><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo-Rizzo P, et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19) Int. Forum Allergy Rhinol. 2021;11:1685&#x2013;1688. doi: 10.1002/alr.22832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alr.22832</ArticleId><ArticleId IdType="pmc">PMC9291310</ArticleId><ArticleId IdType="pubmed">34109765</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, et al. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Skyrud KD, Hern&#xe6;s KH, Telle KE, Magnusson K. Impacts of mild COVID-19 on elevated use of primary and specialist health care services: A nationwide register study from Norway. PLoS ONE. 2021;16(10):e0257926. doi: 10.1371/journal.pone.0257926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257926</ArticleId><ArticleId IdType="pmc">PMC8500442</ArticleId><ArticleId IdType="pubmed">34624023</ArticleId></ArticleIdList></Reference><Reference><Citation>Skyrud K, Telle K, Magnusson M. Impacts of mild and severe COVID-19 on sick leave. Int. J. Epidemiol. 2021;50:1745&#x2013;1747. doi: 10.1093/ije/dyab182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyab182</ArticleId><ArticleId IdType="pmc">PMC8499817</ArticleId><ArticleId IdType="pubmed">34458903</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K, et al. Healthcare use in 700 000 children and adolescents for six months after covid-19: Before and after register based cohort study. BMJ. 2022;376:e066809. doi: 10.1136/bmj-2021-066809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-066809</ArticleId><ArticleId IdType="pmc">PMC8762452</ArticleId><ArticleId IdType="pubmed">35039315</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N. Engl. J. Med. 2022;386:1532&#x2013;1546. doi: 10.1056/NEJMoa2119451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119451</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P., Diaz, J. V. WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis.21, S1473&#x2013;3099(21)00703&#x2013;9 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K, Kumm J, Turkiewicz A, Englund M. A naturally aging knee, or development of early knee osteoarthritis? Osteoarthr. Cartil. 2018;26:1447&#x2013;1452. doi: 10.1016/j.joca.2018.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2018.04.020</ArticleId><ArticleId IdType="pubmed">30041054</ArticleId></ArticleIdList></Reference><Reference><Citation>Norwegian institute of public health. The norwegian emergency preparedness register (BEREDT C19). (2020) https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/.</Citation></Reference><Reference><Citation>Sporaland GL, Mouland G, Bratland B, Rygh E, Reiso H. Allmennlegers bruk av ICPC-diagnoser og samsvar med journalnotatene. Tidsskr Legeforen. 2019 doi: 10.4045/tidsskr.18.0440.</Citation><ArticleIdList><ArticleId IdType="doi">10.4045/tidsskr.18.0440</ArticleId><ArticleId IdType="pubmed">31642635</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus immunisation programme in Norway Rational for the recommendations, Norwegian Insititute of Public Health: Oslo. (2020) https://www.fhi.no/contentassets/9d23593d6ebe443ba12556d3f7284eb8/norwegian-ethics-advisory-report-for-corona-vaccination.pdf.</Citation></Reference><Reference><Citation>Whittaker HR, et al. GP consultation rates for sequelae after acute covid-19 patients managed in the community or hospital in the UK: Population based study. BMJ. 2021;375:e065834. doi: 10.1136/bmj-2021-065834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-065834</ArticleId><ArticleId IdType="pmc">PMC8715128</ArticleId><ArticleId IdType="pubmed">34965929</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando HM, et al. Challenges in defining Long COVID: Striking differences across literature, electronic health records, and patient-reported information. medRxiv 2021.03.20.21253896 (2021) 10.1101/2021.03.20.212538.</Citation></Reference><Reference><Citation>Caspersen IH, Magnus P, Trogstad L. Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort. Eur. J. Epidemiol. 2022 doi: 10.1007/s10654-022-00847-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-022-00847-8</ArticleId><ArticleId IdType="pmc">PMC8872922</ArticleId><ArticleId IdType="pubmed">35211871</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson K, et al. Post-covid medical complaints following infection with SARS-CoV-2 Omicron versus delta variants. Nat. Commun. 2022;13:7363. doi: 10.1038/s41467-022-35240-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35240-2</ArticleId><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>UK health security agency. The effectiveness of vaccination against long covid: a rapid evidence briefing. (2022) https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-retrieve-file.pl?id=fe4f10cd3cd509fe045ad4f72ae0dfff.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>